INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027
Boca Raton, Florida, October 21st, 2026, FinanceWire
Final pre-MAA package submitted to MHRA on October 20, 2026
Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks
US BLA expected to be submitted in Q2, 2027
INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel (CORDStrom), its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has revised prior guidance to indicate that faster-than-expect...
